广州万孚生物技术股份有限公司 证券代码：300482 证券简称：万孚生物 公告编号：2026-015 关于召开 2026 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要提示： 1、本次股东会无增加、变更提案的情况。 2、本次股东会以现场投票和网络投票相结合的表决方式。 3、本次股东会未涉及变更前次股东会决议的情形。 4、中小投资者是指除上市公司董事、高级管理人员以及单独或者合计持有公司 5%以上股份的股东以外 的其他股东。 一、召开会议的基本情况 1、股东会届次：2026 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门 规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 03 月 02 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 03 月 02 日 9 ...

| | | 广州万孚生物技术股份有限公司 本次募投项目变更是公司为应对国内集采常态化挑战、突破国际高端市场 壁垒，并加速从"POCT"向"IVD"战略跨越而做出的主动战略调整。 原募投项目基于公司彼时成熟的 POCT（即时检测）业务需求进行规划， 其研发范畴主要集中于免疫胶体金及免疫荧光等干式免疫平台的原料开发。随 着公司战略重心向 IVD 大检验核心赛道扩张，其行业竞争逻辑已转向系统综合 性能的较量。原项目单一的原料优化模式，难以满足高端市场对整体解决方案 的竞争要求，其产出难以适配公司目前重点布局的高端产线。需打破原有的单 一技术平台边界，将研发体系从"POCT"向"IVD"全场景进行扩容。本次变 更旨在对"原料、试剂、仪器"三大要素进行协同升级与深度耦合，通过推动 现有技术要素的系统化迭代，建立全链条的自主配套与联合调优能力，从而夯 实公司在体外诊断全产业链的综合竞争优势。 综合考虑当前募投项目的实施情况，为充分发挥募集资金使用效果，公司 同意变更部分募投项目内容。上述事项尚需提交股东会审议。具体内容详见同 日刊登于巨潮资讯网（http://www.cninfo.com.cn）上的相关公告。 表决结果： ...

Core Insights - The digital PCR (dPCR) technology is emerging as a significant advancement in nucleic acid detection, providing more precise and sensitive methods for quantitative analysis, addressing limitations of traditional PCR methods [1][10] - The Chinese digital PCR market is projected to grow from 1.584 billion yuan in 2019 to 8.815 billion yuan by 2025, with a compound annual growth rate (CAGR) of 33.1% [1][10] - The growth is driven by technological advantages and supportive national policies, with increasing recognition of its value among researchers and clinicians [1][10] Industry Overview - Digital PCR is categorized into droplet digital PCR (ddPCR) and chip digital PCR (cdPCR), allowing for absolute quantification without relying on standard curves, suitable for single-cell analysis and early cancer diagnosis [3][4] - The technology offers significant advantages over traditional PCR, including higher sensitivity, accuracy, and better tolerance to complex samples [4][5] Market Dynamics - The digital PCR industry is supported by a robust supply chain, with upstream components including essential biological materials and core parts like optical and fluid control components [6] - The midstream involves the research, production, and sales of digital PCR devices, with notable domestic companies like New Yi Biological and Zhenzhun Biological emerging as competitors [6][7] Application Areas - Digital PCR is utilized in various fields, including clinical diagnostics for pathogen detection, research for gene expression analysis, food safety testing, and agricultural applications [7][8] - In clinical settings, it plays a crucial role in early disease diagnosis and monitoring, particularly in oncology and infectious diseases [8] Competitive Landscape - The digital PCR market in China has seen the emergence of several domestic companies, with 16 manufacturers winning bids in 2024, of which 11 are local brands [12][12] - New Yi Biological and Linghang Gene lead in market share, with respective bid shares of 20% and 17.14% [12] Future Trends - Continuous technological innovation is expected to enhance detection efficiency and reduce costs, with advancements in multi-color fluorescence detection and microfluidic chip technology [16][17] - Collaboration among upstream suppliers, midstream manufacturers, and downstream application sectors will foster a synergistic development environment [17] - There is a growing focus on expanding into international markets, with domestic companies aiming to enhance their global presence and competitiveness [18][19]

Core Viewpoint - Wanfu Bio has launched a Nipah virus colloidal gold platform testing kit, which includes both antigen and antibody IgM/IgG testing kits, aimed at enhancing diagnostic capabilities for the Nipah virus [1] Group 1: Product Details - The products have completed sample preparation and will soon be evaluated at international terminals [1] - Both testing kits feature a card-type operation design, allowing for use without professional instruments, enabling healthcare personnel to conduct tests after simple training [1] - The antigen test supports dual sample types: blood and swab, providing results in 15 minutes [1]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The recent policy from the National Healthcare Security Administration aims to transform the role of healthcare insurance from a payer to an innovator, significantly impacting the IVD industry by promoting solutions that integrate "testing + AI + services" [5][51]. - The domestic IVD industry is currently in a bottoming phase, with a strong focus on the growth potential of immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [5][51]. - The report highlights that the biochemical diagnostics sector in China has largely completed its localization process, reducing reliance on foreign technologies [5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 0.14%, ranking 15th among 31 primary industries, while the IVD sector fell by 1.28% [2][10]. - The IVD sector's current PE (ttm) is 39.37X, with a PB (lf) of 1.80X, showing a slight decrease from the previous week [4][31]. Company Performance - Notable performers in the medical services sector include SAIKOSHI (+14.5%), Ruiang Gene (+3.1%), and Rendu Bio (+2.6%), while underperformers include Cap Bio (-6.8%) and Hotgen Bio (-6.4%) [3][26]. - The report suggests focusing on companies like YHLO Biotech and Shengxiang Bio in the immunodiagnostics and molecular diagnostics fields due to their growth potential [5][51]. Market Trends - The report indicates that the IVD industry is experiencing a shift towards integrating new technologies and payment methods, driven by recent policy changes [5][51]. - The overall IVD market is expected to continue its steady growth, with significant opportunities arising from the integration of AI and innovative products [5][51].

Group 1 - The core point of the article is that Wanfu Biology announced the completion of a share reduction plan by its director and senior management personnel, Peng Zhongxiong, who sold 29,700 shares at an average price of 20.77 yuan per share, representing 0.0064% of the company's total share capital [2] Group 2 - The share reduction was executed through a centralized bidding method [2] - The announcement was made on February 6, 2026, indicating the date of the transaction [2]

Group 1 - The core point of the article is that Wanfang Bio announced the completion of a stock reduction plan by its director and senior management personnel, Peng Zhongxiong, who sold a total of 29,700 shares, accounting for 0.0064% of the company's total share capital [1] Group 2 - The stock reduction was executed through a centralized bidding method [1] - The reduction plan has been fully implemented [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-012 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于董事、高级管理人员股份减持计划实施完成的公告 彭仲雄先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 12 月 29 日在巨潮资讯网上披露了《关于公司董事、高级管理人员减持股份的预披露公告》 （公告编号：2025-078），公司董事、高级管理人员彭仲雄先生因个人资金需求， 计划以集中竞价的方式减持公司股份合计不超过 29,700 股（不超过公司剔除回 购专用账户股份数量总股本的 0.0064%）。减持期间为本减持计划公告之日起十 五个交易日后的 3 个月内。 近日公司收到彭仲雄先生发来的《股票减持完成告知函》，获悉其股票减持 计划已实施完成。根据《上市公司股东减持股份管理暂行办法》及《深圳证券交 易所上市公司自律监管指引第 ...

Core Viewpoint - Wanfu Biotech (300482) is focusing on strategic collaborations and technological advancements in the field of AI and gene sequencing to enhance its product offerings and market presence. Group 1: Strategic Collaborations - The company signed a strategic cooperation agreement with Tencent Health in May 2025, aiming to explore AI applications in disease detection, clinical decision support, and family health management [2] - The collaboration with Beiden Medical is seen as a key step to tap into the vast market potential in grassroots healthcare, focusing on optimizing products to meet the core needs of "accurate, fast, simple, and affordable" [4][5] Group 2: Technological Advancements - The company is exploring the integration of AI technology with gene sequencing to improve data analysis and interpretation efficiency, although specific product plans were not disclosed [2][3] - There are plans to develop more user-friendly devices suitable for grassroots healthcare settings, addressing the need for quick identification in rural health centers [4] Group 3: Market Outlook and Growth Targets - The global market for gene sequencing is projected to reach $20.2 billion by 2032, prompting the company to set mid- to long-term growth targets for its gene sequencing business [3] - The company is actively monitoring industry trends and is expected to provide updates on its core products' sales and revenue contributions in future reports [5] Group 4: Financial Insights - On February 5, 2026, Wanfu Biotech's stock closed at 20.65 yuan, down 0.91%, with a trading volume of 68,000 shares and a turnover of 140 million yuan [1] - On the same day, there was a net outflow of 3.77 million yuan from main funds, indicating a slight withdrawal of institutional investment [6]

Group 1 - The company Wanfu Biological (300482) is actively monitoring trends in industrial technology development [1]